The US Food and Drug Administration (FDA) is requiring some Type 2 diabetes drugs to change its product label to include a heart failure risk warning. This “boxed” warning emphasizes that the class of thiazolidinedione drugs may cause or worsen heart failure in certain patients. Drugs in this class included Avandia (rosiglitazone), Actos (pioglitazone) Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepride). These drugs are currently approved in the US for treating type 2 diabetes in combination with diet and exercise. Postmarketing surveillance of these drugs is required by the FDA as a condition of approving these drugs and making them available on market. Postmarketing reports have shown cases of warning signs of heart failure: significant weight gain and edema (water retention and accumulation in organs). Source: FDA.
- Do Mylan shareholders want the CEO to keep raising the price of the EpiPen?
- Theranos’ AACC Presentation: Not the Reboot We Were Hoping For
- Killing Zika Virus Carrying Mosquitoes with Gene Drives?
- Transgender, Cisgender: Where does gender identity come from?
- How Antibiotics Work
- Theranos’ Elizabeth Holmes is Not a Liar
- The Theranos Problem in One WSJ Graphic
- What Pharma Companies Need
- Biotechnology Stock Price Drivers
- What You Need to Know about Your 401K Plan